ArticleAntimicrobial agents and chemotherapy2017

Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment".

M O Fofana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.